Cerebrolysin

Overview

Cerebrolysin is a proprietary mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain, marketed as having neurotrophic, neuroprotective effects. It is approved and used clinically in many countries (Eastern Europe, Asia, and elsewhere) for stroke, dementia, and traumatic brain injury, but it is NOT FDA-approved in the US. Importantly, independent Cochrane reviews have judged the overall evidence to be of very low certainty: pooled trials in vascular dementia and stroke do not clearly establish a clinically meaningful benefit, and at least one review flagged a possible increase in non-fatal serious adverse events. The honest summary is that benefit remains unproven by rigorous independent standards.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Stroke recovery / rehabilitation (approved use in some countries; Cochrane evidence very low certainty and not FDA-reviewed)
• Vascular dementia / cognitive decline (Cochrane evidence very low certainty; not clearly clinically meaningful)
• Traumatic brain injury recovery (marketed/used abroad; independent evidence limited)

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Subjective — daily cognition, focus, and mood check-ins over a baseline period
• WHOOP — recovery score, HRV, and sleep trend
• Labs — discuss relevant clinician-ordered monitoring with your provider rather than self-tracking a single biomarker

Sources & References

1. [1]Cerebrolysin for vascular dementia — Cochrane (CD008900)